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Open access under CC BY license.Since our ancestors began trading several millennia ago,
counterfeit and substandard medicines have been a
recurring problem, with history punctuated by crises
in the supply of anti-microbials, such as fake cinchona
bark in the 1600s and fake quinine in the 1800s. Unfortu-
nately this problem persists, in particular afflicting
unsuspecting patients in ‘developing’ countries. Poor-
quality drugs are a vital (but neglected) public health
problem. They contribute to a ‘crevasse’ between the
enormous effort in therapeutic research and policy de-
cisions and implementation of good-quality medicines.
Introduction
Globalization of the pharmaceutical industry has the
potential to rapidly spread poor-quality medicines world-
wide before adequate detection and intervention are
possible. There are two main categories of poor-quality
medicines: substandard and counterfeit (Box 1). Substan-
dard products arise as a result of lack of expertise, poor
manufacturing practices, or insufficient infrastructure,
whereas counterfeits are the ‘products’ of criminals [1,2].
Counterfeits may contain no active ingredient, incorrect
ingredients, or toxins. The amount of active ingredient
does not provide sufficient information to accurately deter-
mine if a medicine is counterfeit; inspection of the packa-
ging is also required as mislabelling is a key part of the
definition and counterfeits with fake packaging but the
correct amount of active ingredient have been described
(Box 1). In many reports, it is unclear if poor-quality
medicines are counterfeit or substandard, but it is import-
ant that they are correctly classified because they have
different origins and different solutions. Inadequate enfor-
cement, lenient penalties, corruption, ‘spaghetti-like’ trade
arrangements, unregistered medicines, and ignorance of
poor-quality medicines among the public and health
workers exacerbate the situation [1–3].
Prevalence
There are very few published data allowing estimation of
the extent of the problem and the impact on public health
[1–7]. Only 5–15% of the 191 member states of the World
Health Organization (WHO) report cases of counterfeit
drugs [2]. Many data have been interpreted uncritically;Corresponding author: Newton, P.N. (paul@tropmedres.ac).
0165-6147 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.tips.2009.11.005some are inaccurate and do not allow accurate generaliz-
ations about the epidemiology of poor-quality medicines
[1–7].
Counterfeits of most commonly used essential drugs
have been described, with a recent review describing
206 cases of counterfeit anti-infectives from 38 countries
[2]. Of 771 reports of counterfeit medicines received by the
WHO from 1982 to 1999, 48.4% were from the Western
Pacific region, with most being labelled as anti-infectives
[3]. The International Medical Products Anti-Counterfeit-
ing Taskforce (IMPACT) cautioned against using the off-
quoted estimate of 10% of the global supply being counter-
feitt, and suggested that ‘‘many developing countries of
Africa, parts of Asia, and parts of Latin America have areas
where >30% of the medicines on sale can be counterfeit.
Other developing markets, however, have <10%. . .’’[5].
Anti-malarials appear to have been particularly tar-
geted. In a recent epidemic of fake artesunate in mainland
South-East Asia 38%–53% of these vital anti-malarials
obtained from pharmacies and shops were counterfeit,
revealing a wide diversity of counterfeit packaging types
[2,8]. After hundreds of patients with visceral leishmania-
sis failed to respond to ‘miltefosine’ in Bangladesh, cap-
sules were found not to contain miltefosine [9]. Diagnostic
tests have also been faked, including counterfeit lactate
test strips and HIV antibody kits. Counterfeit insecticide-
treated bednets and vaccines (against e.g. Neisseria
meningtidis, influenza and rabies) are of considerable
concern because of their importance in preventing key
diseases [2]. With intimate links between the health of
humans and animals, poor-quality insecticides and veter-
inary medicines suggests unappreciated interrelated con-
sequences for the health of livestock and humans.
Substandard products have also been with us since
medicines were first compounded. They are an inevitable
consequence of inadequate local regulation of the pharma-
ceutical industry and the lack of good manufacturing
practices (GMP) facilities in many ‘developing’ countries
[1,9]. In Venezuela, for example, primaquine tablets were
found to contain 19–168% primaquine, and one patient
developed Plasmodium vivax malaria after taking prima-
quine containing 46% of the stated content [2]. A significant
proportion of sulphadoxine–pyrimethamine tablets avail-
able in Africa are substandard and fail dissolution testing
because of incorrect formulation, resulting in poor oral
bioavailability and reduced efficacy [2].Available online 1 February 2010 99
Box 1. Definitions and examples of poor-quality medicines
[1–3,7]
Counterfeits are ‘‘deliberately and fraudulently mislabelled with
respect to identity and/or source. Counterfeiting can apply to
branded and generic products. Counterfeits may include products
with correct or incorrect ingredients, without active ingredients, with
insufficient active ingredient, or with fake packaging’’ [3,7]. For
example, an antidepressant (fluvoxamine) and a muscle relaxant
(cyclobenzaprine hydrochloride) were labelled as anti-retrovirals in
the Democratic Republic of Congo. One-third to one-half of the a vital
anti-malarial agent artesunate bought in mainland South-East Asia is
counterfeit, containing no or sub-therapeutic active ingredient
Substandard drugs are ‘‘genuine drug products which do not meet
the quality specifications set for them’’ [3,7]. For example, contami-
nated substandard magnesium sulfate leading to Serratia septicae-
mia; 10% of anti-TB medicines contained less than allowed active
ingredient in six TB-endemic countries; and gentamicin-resistant
Pseudomonas aeruginosa in gentamicin eye drops led to severe
eye infections.
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Considering the vast scale of the global pharmaceutical
industry and the incidence of potentially fatal diseases,
any amount of poor-quality medicine is unacceptable
because it increases morbidity and mortality (Box 2).
The impact of poor-quality medicines is most clearly evi-
dent if they contain lethal incorrect active ingredients.
Until recently, it was often assumed that counterfeits were
inert. However, forensic chemistry has demonstrated that
many contain harmful ingredients – as tragically illus-
trated by the death of 500 children after ingesting para-
cetamol containing a renal toxin [2]. Patients may also
suffer adverse effects of unexpected ingredients, e.g. co-
trimoxazole containing diazepam; reused ceftazidime vials
containing streptomycin; and counterfeit artesunate
tablets containing artemisinin, chloramphenicol, parace-
tamol, and metamizole. Patients may be allergic to these
covert pharmaceuticals, or may experience confusing
adverse events. Some substandard drugs contain more
active ingredient than stated [10] and, for anti-infectives
with narrow therapeutic ratios, this may increase the
prevalence of adverse effects.
The use of counterfeit anti-malarials, and the conse-
quent failure of patients to improve, has led to false reports
of drug resistance to malaria [13]. An example of the
potential dangers of sub-therapeutic dosage were illus-
trated when heavier tourists, dosed without taking patient
body weight into account, and not their thinner co-trave-
lers, developed P. vivax relapses [11]. Anti-infectives con-Box 2. Impact of poor-quality medicines
 Increased mortality and morbidity
 Engendering of drug resistance and loss of medicine efficacy
 Loss of confidence in health systems and health workers
 Economic loss for patients, their families, health systems, and the
producers and traders in good-quality medicines
 Adverse effects from incorrect active ingredients
 Waste of enormous human effort and financial outlay in devel-
opment of medicines, optimising dosage, carrying out clinical
trials, discussing policy change, and manufacturing medicines
 Increased burden for health workers, medicine regulatory autho-
rities (MRAs), customs officials and police officers
100taining sub-therapeutic amounts of the active ingredient
(whether counterfeit or substandard) increase the risk of
the selection and spread of drug-resistant pathogens [13].
Selection depends on awide variety of factors, i.e. pathogen
biomass; host immunity; relationships between the drug
pharmacokinetic profile; pharmacodynamic effects on the
pathogen; anti-microbial susceptibility of the the
pathogen; and the fitness of resistant mutants. If resistant
pathogens infect or arise de novowithin a host and encoun-
ter sub-lethal concentrations of a slowly eliminating anti-
microbial, they will have a survival advantage and multi-
ply faster than sensitive pathogens [12]. Although models
of the emergence and spread of resistance to anti-malarial
drugs suggest that poor-quality drugs are important, it is
very difficult to tease apart the effects of themisuse of anti-
infectives by health workers, patient adherence, and poor-
quality drugs. Counterfeits containing no active ingredient
will not provide this ‘drug pressure’, and it is likely that
substandardmedicines aremore important in engendering
resistance. However, fakes containing sub-therapeutic
amounts of the stated ingredient, or incorrect anti-
microbial ingredients, may facilitate the emergence and
spread of drug-resistant pathogens. For diseases treated
with combination therapy (e.g. tuberculosis, HIV, falci-
parum malaria), poor-quality combination medicines risk
the spread of resistance due to the poor-quality active
ingredient and the ‘unprotected’ co-ingredient. Artemisi-
nin derivatives-based combination therapies (ACTs) hold
great hope for controlling malaria in Africa but, most
alarmingly, poor-quality ACTs are already widespread
[2,6,13]. Plasmodium falciparum artesunate resistance
has recently been described on the Thailand–Cambodia
border and the wide use of monotherapy, substandard
artesunate, and fake artesunate containing sub-thera-
peutic quantities of artemisinin and artesunate in
South-East Asia have probably contributed to this poten-
tially disastrous problem [8]. Poor-quality tuberculosis
(TB) drugs [14] are a neglected link between TB treatment,
therapeutic failure and the increasing burden of TB drug
resistance.
Combating the problem
Strengthening medicine regulatory authorities (MRAs),
improving quality of production, and facilitating the avail-
ability of relatively inexpensive, good-quality anti-infec-
tives are likely to be key factors in improving drug quality.
There is an urgent need for data of sufficient sample size
with random sampling design to reliably estimate the
prevalence of poor-quality medicines. Such data are vital
to select appropriate interventions, assess their effective-
ness, and follow changes through time. Recent literature
has concentrated on poor-quality anti-malarials, but it is
likely that other anti-infective medicines are also pro-
foundly affected. We do not know how counterfeit and
substandard medicines compare with respect to their
impact. We also have little information on what proportion
of patients or health workers are aware of the issues in
different societies, and which interventions may be the
most effective.
Sustained political will and financial support for coor-
dinated action from the police, customs officials and MRAs
Update Trends in Pharmacological Sciences Vol.31 No.3is crucial. A recent forensic investigation into the trade in
fake artesunate demonstrated that police, scientists, the
pharmaceutical industry, governments and the WHO can
work together to combat these problems [8]. Although a
wide range of sophisticated quality-assurance markers
have been developed, they are unlikely to be implemented
in the poorest countries. A major limitation is MRA
capacity; WHO estimated that 30% of countries have no
drug regulation or a capacity that hardly functions [2,4,7].
The lack of financial and human resources available to
manyMRAsmakes investigation of poor-quality drugs and
action impossible. There are only two WHO pre-qualified
quality-control medicine analysis laboratories in the whole
of malarious parts of Africa [15]. Support for MRAs and the
development of regional laboratories to allow the regula-
tion of the drug supply will be crucial to allow interven-
tions. The actions necessary to combat substandard drugs
may bemore straightforward because criminal deception is
not involved, but these interventions will involve costly
improvements in GMP and periodical inspections.
Increased provision of free or inexpensive medicines for
key diseases would undercut the counterfeiters and reduce
the criminal financial incentive. The available evidence
suggests that poor-quality essential medicines are having
a very important (but avoidable) toll on health in the
developing world, and that this issue clearly needs to be
taken much more seriously. We remain woefully ignorant
as to how these problems can be addressed.
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